Compare Humana Inc (HUM) vs Nike Inc (NKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Nike Inc — how do they compare? Humana Inc trades at $445 (market cap $46.49B), while Nike Inc trades at $34.79 (market cap $51.60B). The key difference: Humana Inc and Nike Inc are close in size by market cap, and Nike Inc pays the higher dividend (4.72%). Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Nike Inc for 155 Days on average.
| HUM | NKE | |
|---|---|---|
Market Cap | $46.49B | $51.60B |
Volume | 2,567,704 | 43,506,062 |
Sector | Health | Consumer Cyclical |
52-Week High | $409.85 | $69.68 |
52-Week Low | $163.67 | $33.87 |
Typical Hold Time | 53 Days | 155 Days |
Enterprise Value | $53.84B | $54.30B |
Dividend Yield | 0.91% | 4.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $396.51, down 1.92% on the day, with strong technical momentum showing bullish moving averages and key support at $391. The company demonstrates consistent revenue growth reaching $129.7B in 2025, though net margins have compressed to 0.88%. Recent quarterly earnings have exceeded expectations, with Q2 2026 EPS of $7.61 beating estimates of $7.27. Analyst sentiment remains positive with a $432.63 consensus price target representing 9% upside potential from current levels.
The investment case centers on Humana's dominant Medicare Advantage position and consistent revenue growth, though margin pressure and regulatory scrutiny present headwinds. With 43% of analysts maintaining buy ratings and institutional accumulation continuing, the stock offers exposure to healthcare demographics but requires monitoring of enrollment trends and cost management execution.
Nike (NKE) trades at $34.74, up 0.38% on the day, amid a bearish technical signal and mixed earnings history. The stock shows strong profitability with a 43.07% gross margin and 21.56% ROE, but revenue declined to $46.31B in 2025. Recent news highlights challenges in China and EMEA, while analysts maintain a $36.98 consensus target.
Nike's outlook hinges on executing its turnaround strategy to revive growth. Investment opportunities include brand strength and digital initiatives, but risks involve sluggish demand, margin pressure, and intense competition. The stock's valuation appears reasonable with a P/E of 16.44, yet near-term headwinds warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
